Astragaloside IV exerts anti-inflammatory role in endometriosis by downregulating TLR4/NF-κB pathway
| Autor: | Caiwei Xu, Yongping Zhang, Wei Zhang, Ouping Huang, Luxin Liu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Tropical Journal of Pharmaceutical Research. 18:539-545 |
| ISSN: | 1596-9827 1596-5996 |
| DOI: | 10.4314/tjpr.v18i3.14 |
| Popis: | Purpose: To investigate the effect of astragaloside IV administration on the inflammatory response in endometriosis and the underlying mechanism of action. Methods: Mice were divided into two groups: endometriosis (EMs) mice and control mice (n = 12). EMs induction in mice was achieved by transplantation of mouse uterine tissue. The same procedure was performed in control mice except that a separate suture was inserted instead of endometrial tissue. After 5 weeks, EMs mice were treated with or without astragaloside IV (AIV). The tissue lesions in EMs and control mice were stained with hematoxylin and eosin staining. The activation of toll-like receptor 4 (TLR4) and nuclear factor-κB (NF-κB) p65 signaling was evaluated by western blot, while expression of inflammatory cytokines was evaluated by quantitative real-time-polymerase chain reaction (qRT-PCR), and enzyme-linked immunosorbent assay (ELISA). Results: Astragaloside IV repressed the inflammation of murine Ems lesions, and also dampened the activation of TLR4/NF-κB signaling in vivo and vitro (p < 0.01 and p < 0.001, respectively). In addition, the expression levels of inflammatory cytokines (IL-1β, IL-6, Ccl-2, and TNF-α) decreased following AIV treatment in vivo. Conclusion: The results indicate that TLR4/NF-κB signaling pathways are closely related to the inhibition of Ems inflammation by astragaloside IV. Thus, astragaloside IV may be a novel drug for the prevention and treatment of endometrioses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|